JPS62255422A - Nutrition improver containing triglyceride of middle-chain fatty acid as active ingredients - Google Patents
Nutrition improver containing triglyceride of middle-chain fatty acid as active ingredientsInfo
- Publication number
- JPS62255422A JPS62255422A JP61096553A JP9655386A JPS62255422A JP S62255422 A JPS62255422 A JP S62255422A JP 61096553 A JP61096553 A JP 61096553A JP 9655386 A JP9655386 A JP 9655386A JP S62255422 A JPS62255422 A JP S62255422A
- Authority
- JP
- Japan
- Prior art keywords
- chain fatty
- fatty acid
- hypocholesterolemia
- nutritional
- nutrition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 18
- 239000004480 active ingredient Substances 0.000 title claims abstract description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims description 9
- 230000035764 nutrition Effects 0.000 title abstract description 6
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 3
- 229930195729 fatty acid Natural products 0.000 title abstract 3
- 239000000194 fatty acid Substances 0.000 title abstract 3
- 150000004665 fatty acids Chemical class 0.000 title abstract 3
- 206010020961 Hypocholesterolaemia Diseases 0.000 claims abstract description 15
- 239000008280 blood Substances 0.000 claims abstract description 14
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 7
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 5
- 208000002720 Malnutrition Diseases 0.000 claims description 4
- 235000000824 malnutrition Nutrition 0.000 claims description 4
- 230000001071 malnutrition Effects 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 5
- 239000011707 mineral Substances 0.000 abstract description 5
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 5
- 235000013343 vitamin Nutrition 0.000 abstract description 5
- 239000011782 vitamin Substances 0.000 abstract description 5
- 229940088594 vitamin Drugs 0.000 abstract description 5
- 229930003231 vitamin Natural products 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 150000001720 carbohydrates Chemical class 0.000 abstract description 3
- 235000019871 vegetable fat Nutrition 0.000 abstract description 3
- 230000001629 suppression Effects 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 101710184086 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase Proteins 0.000 description 5
- 101710201168 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase Proteins 0.000 description 5
- 101710124867 Malonyl CoA-acyl carrier protein transacylase Proteins 0.000 description 5
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 5
- 235000019485 Safflower oil Nutrition 0.000 description 5
- 239000003813 safflower oil Substances 0.000 description 5
- 235000005713 safflower oil Nutrition 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000013110 gastrectomy Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- -1 long-chain fatty acid triglycerides Chemical class 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
企又上■旦朋分団
本発明は、中鎖脂肪酸トリグリセリドを有効成分として
含有する栄養改善剤、特に血中脂質量低下の抑制及び低
コレステロール血症の治療に利用するための栄ｌ改昇剤
に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention is a nutritional improving agent containing medium chain fatty acid triglyceride as an active ingredient, and is particularly useful for suppressing a decrease in blood lipid levels and treating hypocholesterolemia. Concerning an elegance improving agent.
技術的背景
中鎖脂肪酸トリグリセリド（Ｍｅｄｉｕｍ Ｃｈａｉｎ
Ｔｒｉｇ−１ｙｃｅｒｉｄｅｓ 、以下ＭＣＴと略記
する）は、一般の脂肪成分である長鎖脂肪酸トリグリセ
リドとその吸収経路及び代謝を本質的に異にするため、
近年、栄養療法の有効な成分として注目されている。Technical Background Medium Chain Triglyceride
Trig-lycerides (hereinafter abbreviated as MCT) have essentially different absorption routes and metabolism from long-chain fatty acid triglycerides, which are common fat components.
In recent years, it has attracted attention as an effective ingredient in nutritional therapy.
ＭＣＴの栄養学的な特色は、一般の脂肪並の高いカロリ
ーを有しながら、消化吸収がＩ！質及び蛋白質並あるい
はそれ以上に迅速かつ容易に行われる点にある。すなわ
ち、ＭＣＴの消化には一般脂肪の場合のような胆汁酸及
び膵リパーゼの必要がない。更に、ＭＣＴはその吸収に
際してはカイロミクロンの形成を必要とせずにトリグリ
セリドの形態のままで吸収されるので、リンパ管を経由
することなく腸上皮細胞から門脈を経て肝臓に運ばれる
。そしてＭＣＴは、吸収後速やかに肝臓で酸化されてエ
ネルギーとして利用されるので、脂肪咀礒にはほとんど
蓄積されない。The nutritional characteristics of MCTs are that they have a high calorie content similar to that of regular fats, but are easily digested and absorbed! The advantage is that it can be done as quickly and easily as, or even more than, quality and protein. That is, digestion of MCTs does not require bile acids and pancreatic lipase, as is the case with common fats. Furthermore, since MCTs are absorbed in the form of triglycerides without requiring the formation of chylomicrons, MCTs are transported from intestinal epithelial cells to the liver via the portal vein without passing through the lymphatic vessels. After MCT is absorbed, it is quickly oxidized in the liver and used as energy, so it is hardly accumulated in fat mass.
し１こがって、ＭＣＴは、吸収容易な高カロリーのエネ
ルギー源として、応での栄養補給に用いちれるようにな
った。また、ＭＣＴは、上述したような特性から、吸収
不全症候群、リンパ管系障害や脂肪誘起性高脂血症、高
コレステロール血症等の治療に際しての栄養補給にも用
いられている。As a result, MCTs have come to be used as an easily absorbable, high-calorie energy source for nutritional supplementation. Furthermore, due to the above-mentioned properties, MCT is also used for nutritional supplementation in the treatment of malabsorption syndrome, lymphatic system disorder, fat-induced hyperlipidemia, hypercholesterolemia, and the like.
ところで、近年、高コレステロール血症が健康上の問題
点として言われている一方で、低コレステロール血症な
る病態が見出されている。By the way, in recent years, while hypercholesterolemia has been said to be a health problem, a pathological condition called hypocholesterolemia has been discovered.
すなわち、コレステロール自体は、血中脂質成分の中で
トリグリセリドやリン脂質と共に重要な成分であって、
その量が一定量以下に低下すると低コレステロール組症
という病態がみられるようになる。この病態には、−成
性の家族性低コレステロール血症と二次性の続発性低コ
レステロール血症とがあり、特に続発性低コレステロー
ル血症は、肝細胞障害、吸収不全症候群、消化管手術後
及び貧血等により誘発されやすい。In other words, cholesterol itself is an important component along with triglycerides and phospholipids among blood lipid components.
When the amount drops below a certain level, a condition called hypocholesterolemia occurs. This condition includes - adult familial hypocholesterolemia and secondary hypocholesterolemia. Secondary hypocholesterolemia is particularly important due to hepatocellular damage, malabsorption syndrome, and gastrointestinal surgery. It is likely to be induced by post-inflammatory symptoms and anemia.
日が解ンしようとする課
本発明は、上述した低栄養状態にみられる血中脂質量の
低下に因る低コレステロール血症の治療においで有効に
利用し得る栄養改善剤を提供することを課題とするもの
である。The present invention aims to provide a nutrition improving agent that can be effectively used in the treatment of hypocholesterolemia caused by a decrease in the amount of blood lipids observed in the above-mentioned malnutrition state. That is.
本発明者は、ＭＣＴを有効成分として含む栄養剤が、上
記低コレステロール血症の治療上有効であるとの知見を
得て、本発明をなすに至った。The present inventors have found that a nutritional supplement containing MCT as an active ingredient is effective in treating hypocholesterolemia, and has accomplished the present invention.
以下本発明の詳細な説明する。The present invention will be explained in detail below.
ユ皿色盪底
本発明の特徴は、中鎖脂肪酸トリグリセリド（ＭＣＴ）
を有効成分として含有する、低栄養状態に起因する血中
脂質量低下の抑制及び低コレステロール組症の治療に利
用される栄養改善剤にある。The feature of the present invention is medium chain fatty acid triglyceride (MCT).
The present invention provides a nutrition improving agent which contains as an active ingredient, and which is used to suppress a decrease in blood lipid levels caused by malnutrition and to treat hypocholesterolemia.
課伺を解決するための は
本発明に係る栄養剤は、ＭＣＴを３乃至２０重星％〜好
ましくは６乃至１５重量％含をしているものであって、
ＭＣＴの含有量が３重量％より低いと低栄養状態におけ
る血中脂質量低下の抑制ができなくなり、一方２０重蟹
％より多くても上記抑制効果が更に向上しないので無意
味となる。In order to solve the problem, the nutritional supplement according to the present invention contains MCT in an amount of 3 to 20% by weight, preferably 6 to 15% by weight,
If the content of MCT is lower than 3% by weight, it will not be possible to suppress the decrease in blood lipid levels in a malnourished state, while if it is higher than 20% by weight, the above-mentioned suppressive effect will not be further improved, so it will be meaningless.
本発明では、ＭＣＴに加えて、通常栄養剤に用いられる
蛋白質、アミノ酸、ペプチド、植物性脂肪、糖質、ミネ
ラル類、ビタミン類、更には必要に応じて乳化剤、安定
剤を添加、含有させ得る。In the present invention, in addition to MCT, proteins, amino acids, peptides, vegetable fats, carbohydrates, minerals, vitamins, which are commonly used in nutritional supplements, and further emulsifiers and stabilizers may be added and contained as necessary. .
ここで用いる蛋白質、アミノ酸並びにペプチドは窒素源
として利用されるものであって、消化、吸収の点からす
ればペプチドが好ましい、アミノ酸は、栄養剤中のアミ
ノ酸バランスを調整する目的で用いられる。The proteins, amino acids, and peptides used here are used as nitrogen sources, and peptides are preferred from the viewpoint of digestion and absorption.Amino acids are used for the purpose of adjusting the amino acid balance in the nutritional supplement.
本発明で用いる糖質としては、グルコースのような単糖
類、ショ糖、マルトースのような三糖類、デキストリン
、α化でんぷんのような多糖類を例示でき、これらは単
独又は混合して用いてもよい。Examples of carbohydrates used in the present invention include monosaccharides such as glucose, sucrose, trisaccharides such as maltose, dextrins, and polysaccharides such as pregelatinized starch, which may be used alone or in combination. good.
例えば、グルコースに乳糖やガラクトース等を混合して
用いることもできる。For example, lactose, galactose, etc. can be mixed with glucose.
また、植物性脂肪を用いる場合は、ＭＣＴには必須脂肪
酸が全く含まれていないことから、リノール酸を含有す
る脂肪、例えばサフラワー油、コーン油、大豆油、綿実
油、サンフラワー油等を用いることが好ましい。In addition, when using vegetable fat, since MCT does not contain any essential fatty acids, a fat containing linoleic acid, such as safflower oil, corn oil, soybean oil, cottonseed oil, sunflower oil, etc. is used. It is preferable.
上記各成分に加えて添加されるミネラル類としては、ナ
トリウム、カリウム、マグネシウム、カルシウム、リン
、塩素、鉄、亜鉛、銅、マンガン、コバルト、モリブデ
ン、クロム、セレン等を例示でき、また、ビタミン類と
しては、ビタミンＡ、Ｄ、Ｅ、、に、、Ｂ＋ 、Ｂｚ
、Ｂｂ 、Ｂ＋□、Ｃ，ナイアシン、葉酸、ビオチン、
パントテン酸等を例示し得る。Examples of minerals added in addition to the above ingredients include sodium, potassium, magnesium, calcium, phosphorus, chlorine, iron, zinc, copper, manganese, cobalt, molybdenum, chromium, selenium, etc. For example, vitamins A, D, E, , B+, Bz
, Bb , B+□, C, niacin, folic acid, biotin,
Examples include pantothenic acid.
本発明に係る栄養改善剤は、ＭＣＴを主要成分としたも
のに、上掲の各成分を適宜配合して、固形形態、粉末形
態もしくは液状形態に調製したものを、低コレステロー
ル血症患者の低栄養状態の改善に供して、血中脂質量低
下を抑制すると共に低コレステロール血症の治療効果を
高めるのに利用される。The nutritional improvement agent according to the present invention is prepared by appropriately blending each of the above-mentioned components with MCT as a main component and preparing it in a solid, powdered or liquid form, and is used to reduce cholesterol levels in patients with hypocholesterolemia. It is used to improve nutritional status, suppress a decrease in blood lipid levels, and enhance the therapeutic effect of hypocholesterolemia.
次に、本発明による栄養改蕃剤の血中脂質量低下の抑制
効果を試験した結果を示す。Next, the results of testing the effect of the nutritional modifier according to the present invention on suppressing a decrease in blood lipid levels will be shown.
試験方法：
実験動物として体重約１５０８のＳＤ系誰ラットを用い
、胃全摘処置を行って低栄養状態のモデルとした。Test method: SD rats weighing approximately 1,508 kg were used as experimental animals and underwent total gastrectomy to serve as a model of malnutrition.
実験動物群は８匹を一群とし、冑全摘群３群と、正常ラ
ットを用いた正常対照群の１群の計４群とした。The experimental animals were divided into 4 groups: 8 animals per group, 3 groups of total amputees, and 1 group of normal control groups using normal rats.
胃全摘群には表１に示す対照飼料と、本発明による試験
飼料ｌ乃至■を投与し、正常対照群には対照飼料を投与
した。The total gastrectomy group was administered the control feed shown in Table 1 and the test feeds 1 to 1 according to the present invention, and the normal control group was administered the control feed.
上記により各飼料を１ケ月間投与し、飼育終了後、各群
のラットの血中脂質の量を測定した。血中脂質量の測定
は、実験動物をネンブタール麻酔下においた後大静脈か
ら採血した血液を血清分離後常法により行った。結果は
表２に示すとおりである。Each feed was administered as described above for one month, and after the end of the feeding, the amount of blood lipids in the rats of each group was measured. The amount of lipids in the blood was measured by a conventional method after the experimental animals were placed under Nembutal anesthesia, blood was collected from the vena cava, and the serum was separated. The results are shown in Table 2.
表２にみられるとおり、本発明に従ってＭＣＴを含有さ
せた飼料を投与した群の血中脂ＭＮ低下の抑制効果が明
らかに認められる。As seen in Table 2, the effect of suppressing the decrease in blood lipid MN in the group to which the feed containing MCT according to the present invention was administered was clearly observed.
以下に実施例を示して本発明による栄養改善剤の調製を
具体的に説明する。EXAMPLES The preparation of the nutritional improving agent according to the present invention will be specifically explained below with reference to Examples.
実施例１
粉末形態の栄養改善剤の調製：
中鎖脂肪酸トリグリセリド １２ ｋｇサフラワ
ー油 ３ ｋｇ酸カゼイン
１９．７ ｋ、。Example 1 Preparation of a nutritional improver in powder form: Medium chain fatty acid triglyceride 12 kg Safflower oil 3 kg Acid casein
19.7k,.
ＤＬ−メチオニン ０．３ ｋｇデキスト
リン ６４ ｋｇビタミン類
１ ｋｇミネラルＭ
５ ｋｇ上記配合で混合粉末化して製
品とした。また、混合に際しては、酸カゼインを適当星
のＮａ２ＣＯ−＋又はに、ＣＯ３の水溶液に溶解し、こ
れに中鎖脂肪酸トリグリセリド及びサフラワー油を加え
、均質化した後噴霧乾燥又は凍結乾燥により乾燥し、次
いでこれと残余の成分を■ブレンダーで混合して製品と
した。DL-Methionine 0.3 kg Dextrin 64 kg Vitamins
1 kg mineral M
5 kg of the above-mentioned mixture was mixed and powdered to make a product. In addition, when mixing, acid casein is dissolved in an aqueous solution of Na2CO-+ or CO3, medium-chain fatty acid triglyceride and safflower oil are added thereto, homogenized, and then dried by spray drying or freeze drying. Next, this and the remaining ingredients were mixed in a blender to form a product.
実施例２
液状形態の栄養改善剤の調製：
中鎖脂肪酸トリグリセリド ５．４ ｋｇサフラ
ワー油 １．３５ ｋｇカゼイン加水分
解物 ８．８７ ｋｇＤ Ｌ−メチオニン
０．１４ ｋｇデキストリン
２８．８ ｋｇグリセリン ０．
２ ｋｇビタミン類 １
ｋｇミ＝ラルｖ４２．２５ ｋｇ
乳化剤 ０．２ ｋｇ上記配合
のものを水１００１に添加し、均質機で混合して製品と
した。Example 2 Preparation of a nutritional improver in liquid form: Medium chain fatty acid triglyceride 5.4 kg Safflower oil 1.35 kg Casein hydrolyzate 8.87 kg D L-methionine
0.14 kg dextrin
28.8 kg glycerin 0.
2 kg vitamins 1
kg Mi-Ral v42.25 kg Emulsifier 0.2 kg The above formulation was added to 100ml of water and mixed in a homogenizer to obtain a product.
実施例３
固形形態の栄養改善剤の調製：
中鎖脂肪酸トリグリセリド １２ ｋｇサフラワ
ー油 ３ ｋｇ酸カゼイン
１９．７ ｋｇＤ １．− メチオニ７
０．３ ｋｇα−コーンスターチ
５４ ｋｇシ ＝＋ｉ店
１０ ｋｇビタミ
ン類 １ ｋｇミネラル類
５ ｋｇ上記配合のものを均質
に混合し、加湿・加温できる成型機又はエクストルーダ
で固形状として製品とした。Example 3 Preparation of a nutritional improver in solid form: Medium chain fatty acid triglycerides 12 kg Safflower oil 3 kg Acid casein
19.7 kgD 1. - Methioni 7
0.3 kg α-cornstarch
54 kg = +i store
10 kg vitamins 1 kg minerals
5 kg of the above formulation was mixed homogeneously and made into a solid product using a molding machine or extruder capable of humidification and heating.
Claims (2)
する、低栄養状態に起因する血中脂質量低下の抑制及び
低コレステロール血症の治療のための栄養改善剤。(1) A nutritional improving agent for suppressing a decrease in blood lipid levels caused by malnutrition and for treating hypocholesterolemia, which contains medium chain fatty acid triglyceride as an active ingredient.
有する特許請求の範囲第（１）項記載の栄養改善剤。(2) The nutritional improving agent according to claim (1), which contains 3 to 20% by weight of medium chain fatty acid triglyceride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61096553A JPH078803B2 (en) | 1986-04-25 | 1986-04-25 | Hypocholesterolemia treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61096553A JPH078803B2 (en) | 1986-04-25 | 1986-04-25 | Hypocholesterolemia treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62255422A true JPS62255422A (en) | 1987-11-07 |
| JPH078803B2 JPH078803B2 (en) | 1995-02-01 |
Family
ID=14168260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61096553A Expired - Lifetime JPH078803B2 (en) | 1986-04-25 | 1986-04-25 | Hypocholesterolemia treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH078803B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02134326A (en) * | 1988-11-14 | 1990-05-23 | Snow Brand Milk Prod Co Ltd | Rectal nutrient for highly stressed state |
| WO2002094039A1 (en) * | 2001-05-18 | 2002-11-28 | The Nisshin Oillio, Ltd. | Food or beverage for ameliorating poor protein/energy nutrition |
| WO2004000299A1 (en) * | 2002-06-19 | 2003-12-31 | The Nisshin Oillio Group, Ltd. | Body fat degradation promoters and foods and drinks |
| JPWO2018207921A1 (en) * | 2017-05-12 | 2019-11-07 | 日清オイリオグループ株式会社 | Total ketone body concentration increasing agent, oil and fat composition, pharmaceutical composition, food composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5791915A (en) * | 1980-09-24 | 1982-06-08 | Roussel Uclaf | Novel lipid composition useful for dietetics, resuscitation and treatment |
| JPS59210025A (en) * | 1983-05-13 | 1984-11-28 | Taiyo Kagaku Kk | Production of emulsified composition of medium-chain triglyceride |
-
1986
- 1986-04-25 JP JP61096553A patent/JPH078803B2/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5791915A (en) * | 1980-09-24 | 1982-06-08 | Roussel Uclaf | Novel lipid composition useful for dietetics, resuscitation and treatment |
| JPS59210025A (en) * | 1983-05-13 | 1984-11-28 | Taiyo Kagaku Kk | Production of emulsified composition of medium-chain triglyceride |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02134326A (en) * | 1988-11-14 | 1990-05-23 | Snow Brand Milk Prod Co Ltd | Rectal nutrient for highly stressed state |
| WO2002094039A1 (en) * | 2001-05-18 | 2002-11-28 | The Nisshin Oillio, Ltd. | Food or beverage for ameliorating poor protein/energy nutrition |
| WO2004000299A1 (en) * | 2002-06-19 | 2003-12-31 | The Nisshin Oillio Group, Ltd. | Body fat degradation promoters and foods and drinks |
| JP2004075653A (en) * | 2002-06-19 | 2004-03-11 | Nisshin Oillio Ltd | Adipose decomposition accelerator and food or beverage |
| JPWO2018207921A1 (en) * | 2017-05-12 | 2019-11-07 | 日清オイリオグループ株式会社 | Total ketone body concentration increasing agent, oil and fat composition, pharmaceutical composition, food composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH078803B2 (en) | 1995-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107708447B (en) | Large lipid globule nutritional product comprising vegetable fat encapsulated by milk phospholipids for improving gastric emptying | |
| US20140323574A1 (en) | Infant formula with high sn-2 palmitate and oligofructose | |
| WO2002047614A2 (en) | Nutritional composition for improving the efficacy of a lipase inhibitor | |
| Takeuchi et al. | Bovine lactoferrin reduces plasma triacylglycerol and NEFA accompanied by decreased hepatic cholesterol and triacylglycerol contents in rodents | |
| EP3280277B1 (en) | Use of a nutritional composition with large lipid globules comprising vegetable fat coated with milk phospholipids for lipid digestion | |
| JP3544493B2 (en) | Nutrition composition for infants | |
| CA3130026A1 (en) | Fat composition and nutritional composition based thereon | |
| Lefevre et al. | Different effects of zinc and copper deficiency on composition of plasma high density lipoproteins in rats | |
| US11877587B2 (en) | Infant nutrition with hydrolysed protein, ionic calcium and palmitic acid | |
| US20040014733A1 (en) | Hydrothermically processed compositions containing phytosterols | |
| CA2340223A1 (en) | Nutritional compositions for preventing or treating hyperlipoproteinemia | |
| JP3920969B2 (en) | Nutritional composition | |
| JPS62255422A (en) | Nutrition improver containing triglyceride of middle-chain fatty acid as active ingredients | |
| US20030003131A1 (en) | Method for manufacture of free-flowing powder containing water-dispersible sterols | |
| CN110584120A (en) | Bone health composition | |
| EP3232819B1 (en) | Infant nutrition with hydrolysed protein and palmitic acid | |
| JPH10262607A (en) | Nutrient composition for infant | |
| JP2846563B2 (en) | Powdered low protein nutritional food composition | |
| Beare-Rogers | Dietary fat requirements in health and development | |
| JPH0335907B2 (en) | ||
| JP2001029011A (en) | Nutrient composition | |
| JP2518632B2 (en) | Vitamin K easily absorbable nutritional composition containing medium chain fatty acid triglyceride as active ingredient | |
| JP2003516946A (en) | Compositions for improving the proliferative response during gastrointestinal adaptation and use in short bowel syndrome | |
| CN113615832A (en) | Composition suitable for convalescent period of hyperlipemia type acute pancreatitis patient and preparation method thereof | |
| IMAIZUMI | MICHIHIRO SUGANO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |